U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07270822) titled 'Screening for MASLD-related Advanced Fibrosis in Type 2 Diabetes' on Sept. 24.
Brief Summary: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the global adult population, 25-30% of whom suffer from metabolic dysfunction-associated steatohepatitis (MASH), increasing the risk of progression to advanced fibrosis (AF) (fibrosis stage F3 or cirrhosis F4). Screening for AF is justified because it is associated with an increased risk of overall, hepatic, and cardiovascular mortality and therefore constitutes a public health issue.
Patients with type 2 diabetes (T2D) are identified as a priority...